OBJECTIVES:Nocturia is prevalent and bothersome in men with lower urinary tract symptoms suggestive of BPH (LUTS/BPH). α-Adrenoceptor antagonists without subtype selectivity have inconsistently shown significant effects on nocturia in these patients. We explored the effects of the α1A-adrenoceptor subtype-selective antagonist silodosin on nocturia by analyzing three placebo-controlled registration studies. METHODS: Responses to question 7 of the IPSS questionnaire were analyzed for the entire study population and patients with ≥ 2 voids/night at baseline. Improvement/worsening rates for nocturia were calculated for once-daily silodosin 8 mg and placebo. Silodosin effects on the mean number of nocturnal voids were compared with placebo, and the number of patients in whom nocturia was reduced to <2 times was calculated. RESULTS: In total, 1,479 men were treated withsilodosin or placebo; 1,266 men (85 %) had ≥ 2 voids/night at baseline. Compared to placebo, more men treated with silodosin reported about nocturia improvement (53.4 vs. 42.8 %, p < 0.0001) and fewer patients about worsening (9.0 vs. 14.3 %, p < 0.0001). Silodosin significantly reduced nocturia within each study and pooled cohort compared to placebo (p < 0.001). In men with ≥ 2 nocturnal voids at baseline, 61 and 49 % of patients with silodosin and placebo had reductions of ≥ 1 voids/night, respectively (p = 0.0003), and significantly more patients with silodosin had <2 nocturia episodes at study end compared to placebo (29.3 vs. 19.0 %; p = 0.0002). CONCLUSIONS: Although a weak impact on nocturia is already known from α-adrenoceptor antagonists without subtype selectivity, the individual placebo-controlled studies and the pooled data analysis showed that the α1A-adrenoceptor subtype-selective antagonist silodosin consistently and significantly improves nocturia in men with LUTS/BPH.
RCT Entities:
OBJECTIVES:Nocturia is prevalent and bothersome in men with lower urinary tract symptoms suggestive of BPH (LUTS/BPH). α-Adrenoceptor antagonists without subtype selectivity have inconsistently shown significant effects on nocturia in these patients. We explored the effects of the α1A-adrenoceptor subtype-selective antagonist silodosin on nocturia by analyzing three placebo-controlled registration studies. METHODS: Responses to question 7 of the IPSS questionnaire were analyzed for the entire study population and patients with ≥ 2 voids/night at baseline. Improvement/worsening rates for nocturia were calculated for once-daily silodosin 8 mg and placebo. Silodosin effects on the mean number of nocturnal voids were compared with placebo, and the number of patients in whom nocturia was reduced to <2 times was calculated. RESULTS: In total, 1,479 men were treated with silodosin or placebo; 1,266 men (85 %) had ≥ 2 voids/night at baseline. Compared to placebo, more men treated with silodosin reported about nocturia improvement (53.4 vs. 42.8 %, p < 0.0001) and fewer patients about worsening (9.0 vs. 14.3 %, p < 0.0001). Silodosin significantly reduced nocturia within each study and pooled cohort compared to placebo (p < 0.001). In men with ≥ 2 nocturnal voids at baseline, 61 and 49 % of patients with silodosin and placebo had reductions of ≥ 1 voids/night, respectively (p = 0.0003), and significantly more patients with silodosin had <2 nocturia episodes at study end compared to placebo (29.3 vs. 19.0 %; p = 0.0002). CONCLUSIONS: Although a weak impact on nocturia is already known from α-adrenoceptor antagonists without subtype selectivity, the individual placebo-controlled studies and the pooled data analysis showed that the α1A-adrenoceptor subtype-selective antagonist silodosin consistently and significantly improves nocturia in men with LUTS/BPH.
Authors: Philip van Kerrebroeck; Paul Abrams; David Chaikin; Jenny Donovan; David Fonda; Simon Jackson; Poul Jennum; Theodore Johnson; Gunnar Lose; Anders Mattiasson; Gary Robertson; Jeff Weiss Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Varant Kupelian; John T Wei; Michael P O'Leary; Jens Peter Norgaard; Raymond C Rosen; John B McKinlay Journal: Eur Urol Date: 2011-09-10 Impact factor: 20.096
Authors: Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams Journal: Eur Urol Date: 2006-10-02 Impact factor: 20.096
Authors: Eric S Rovner; Karl Kreder; David O Sussman; Steven A Kaplan; Martin Carlsson; Tamara Bavendam; Zhonghong Guan Journal: J Urol Date: 2008-07-17 Impact factor: 7.450
Authors: Theodore M Johnson; Pamela K Burrows; John W Kusek; Leroy M Nyberg; J Lisa Tenover; Herbert Lepor; Claus G Roehrborn Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Matthias Oelke; Claus G Roehrborn; Carlos D'Ancona; Timothy H Wilson; Ramiro Castro; Michael Manyak Journal: World J Urol Date: 2014-06-06 Impact factor: 4.226
Authors: Rita Matos; Paula Serrão; Larissa Rodriguez; Lori Ann Birder; Francisco Cruz; Ana Charrua Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-05-31 Impact factor: 3.000
Authors: Matthias Oelke; Claus G Roehrborn; Carlos D'Ancona; Timothy H Wilson; Ramiro Castro; Michael Manyak Journal: World J Urol Date: 2014-05-08 Impact factor: 4.226
Authors: Siri Drangsholt; Maria Juliana Arcila Ruiz; Benoit Peyronnet; Nirit Rosenblum; Victor Nitti; Benjamin Brucker Journal: World J Urol Date: 2018-10-04 Impact factor: 4.226
Authors: Matthias Oelke; Erika Adler; Daniela Marschall-Kehrel; Thomas R W Herrmann; Richard Berges Journal: World J Urol Date: 2014-10 Impact factor: 4.226